Sandre Svatun Lirhus1, Marte Lie Høivik2, Bjørn Moum2,3, Hans Olav Melberg1. 1. a Institute of Health and Society , University of Oslo , Oslo , Norway. 2. b Department of Gastroenterology , Oslo University Hospital , Oslo , Norway. 3. c Institute of Clinical Medicine , University of Oslo , Oslo , Norway.
Abstract
BACKGROUND AND AIMS: During the last decades, substantial progress has been made in both medical and surgical treatment of inflammatory bowel disease (IBD). The aim of this study was to determine the use of anti-TNFs and surgery during the first 3 years after diagnosis in IBD patients across the four health regions in Norway using nationwide patient registry data. METHODS: This study used nationwide data from the Norwegian Patient Registry. Cumulative incidence of anti-TNF exposure and major surgery was calculated for patients diagnosed in 2010-2012. The analyses were stratified by diagnosis and health region. All patients were followed for an equal period of 3 years from diagnosis. RESULTS: The study population included 8,257 IBD patients first registered between 2010 and 2012, of whom 2,829 were diagnosed with Crohn's disease (CD) and 5,428 with ulcerative colitis (UC). Across Norway's health regions, the cumulative incidence of major surgery after 3 years varied from 11.4% to 17.1% for CD and from 4.6% to 6.9% for UC. The cumulative incidence of anti-TNF exposure varied from 20.9% to 31.4% for CD and from 8.0% to 13.5% for UC. The region with the lowest anti-TNF use had the highest surgery rates for both UC and CD. CONCLUSIONS: Cumulative incidence of anti-TNF exposure and surgery varied significantly across Norway's health regions during the three first years after IBD diagnosis.
BACKGROUND AND AIMS: During the last decades, substantial progress has been made in both medical and surgical treatment of inflammatory bowel disease (IBD). The aim of this study was to determine the use of anti-TNFs and surgery during the first 3 years after diagnosis in IBDpatients across the four health regions in Norway using nationwide patient registry data. METHODS: This study used nationwide data from the Norwegian Patient Registry. Cumulative incidence of anti-TNF exposure and major surgery was calculated for patients diagnosed in 2010-2012. The analyses were stratified by diagnosis and health region. All patients were followed for an equal period of 3 years from diagnosis. RESULTS: The study population included 8,257 IBDpatients first registered between 2010 and 2012, of whom 2,829 were diagnosed with Crohn's disease (CD) and 5,428 with ulcerative colitis (UC). Across Norway's health regions, the cumulative incidence of major surgery after 3 years varied from 11.4% to 17.1% for CD and from 4.6% to 6.9% for UC. The cumulative incidence of anti-TNF exposure varied from 20.9% to 31.4% for CD and from 8.0% to 13.5% for UC. The region with the lowest anti-TNF use had the highest surgery rates for both UC and CD. CONCLUSIONS: Cumulative incidence of anti-TNF exposure and surgery varied significantly across Norway's health regions during the three first years after IBD diagnosis.
Authors: Luca Di Martino; Abdullah Osme; Sarah Kossak-Gupta; Theresa T Pizarro; Fabio Cominelli Journal: Cell Mol Gastroenterol Hepatol Date: 2019-06-07
Authors: Eduard Brunet; Emili Vela; Luigi Melcarne; Laura-Patricia Llovet; Anna Puy; Montserrat Clèries; Caridad Pontes; Pilar García-Iglesias; Albert Villòria; Gilaad G Kaplan; Xavier Calvet Journal: Ann Med Date: 2022-12 Impact factor: 5.348
Authors: Reidar Fossmark; Maya Olaisen; Tom Christian Martinsen; Hans Olav Melberg Journal: Therap Adv Gastroenterol Date: 2021-06-28 Impact factor: 4.409
Authors: Lester Tsai; Christopher Ma; Parambir S Dulai; Larry J Prokop; Samuel Eisenstein; Sonia L Ramamoorthy; Brian G Feagan; Vipul Jairath; William J Sandborn; Siddharth Singh Journal: Clin Gastroenterol Hepatol Date: 2020-10-27 Impact factor: 13.576